Dimensional Fund Advisors LP boosted its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 459.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,239,110 shares of the biopharmaceutical company’s stock after acquiring an additional 1,017,573 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.21% of Sangamo Therapeutics worth $14,224,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in shares of Sangamo Therapeutics by 1.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 454,735 shares of the biopharmaceutical company’s stock valued at $7,708,000 after purchasing an additional 7,472 shares during the last quarter. California Public Employees Retirement System grew its stake in shares of Sangamo Therapeutics by 25.9% in the fourth quarter. California Public Employees Retirement System now owns 132,230 shares of the biopharmaceutical company’s stock valued at $1,518,000 after buying an additional 27,200 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Sangamo Therapeutics by 7.9% in the third quarter. Teachers Advisors LLC now owns 1,000,485 shares of the biopharmaceutical company’s stock valued at $16,958,000 after buying an additional 73,264 shares in the last quarter. Tekla Capital Management LLC boosted its position in Sangamo Therapeutics by 40.5% during the fourth quarter. Tekla Capital Management LLC now owns 241,538 shares of the biopharmaceutical company’s stock worth $2,773,000 after purchasing an additional 69,649 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Sangamo Therapeutics by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock valued at $1,792,000 after acquiring an additional 7,817 shares during the period. 57.18% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sangamo Therapeutics stock traded down $0.18 on Monday, reaching $10.59. 1,449,174 shares of the company’s stock were exchanged, compared to its average volume of 2,032,145. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04. Sangamo Therapeutics Inc has a 52 week low of $6.26 and a 52 week high of $19.25. The business has a 50-day moving average price of $9.67. The firm has a market cap of $1.24 billion, a P/E ratio of -15.13 and a beta of 2.99.
Several research analysts have commented on the company. Wedbush set a $11.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Sunday, June 23rd. ValuEngine upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $13.33.
In other news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares of the company’s stock, valued at $305,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Story: Market Capitalization and Individual Investors
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.